Free Shipping in the U.S. for orders over $1000.  Shop Now>>

Receptor transfer between immune cells by autoantibody-enhanced, CD32-driven trogocytosis is hijacked by HIV-1 to infect resting CD4 T cells

Manuel Albanese 1,2,20Hong-Ru Chen 1,20,∗Madeleine Gapp 1,20Maximilian Muenchhoff 1,3Hsiu-Hui Yang 1David Peterhoff 4Katja Hoffmann 5Qianhao Xiao 1Adrian Ruhle 1Ina Ambiel 6,7Stephanie Schneider 1Ernesto Mejías-Pérez 1Marcel Stern 1Paul R Wratil 1Katharina Hofmann 1Laura Amann 1Linda Jocham 1Thimo Fuchs 1Alessandro F Ulivi 8Simon Besson-Girard 9Simon Weidlich 10Jochen Schneider 10Christoph D Spinner 3,10Kathrin Sutter 11Ulf Dittmer 11Andreas Humpe 12Philipp Baumeister 13Andreas Wieser 3,14,15Simon Rothenfusser 16Johannes Bogner 3,17Julia Roider 3,17Percy Knolle 3,18Hartmut Hengel 5Ralf Wagner 4Vibor Laketa 7,19Oliver T Fackler 6,7,∗∗Oliver T Keppler 1,3,21,∗∗∗


10.1016/j.xcrm.2024.101483

Posted: April 4, 2024


Summary

Immune cell phenotyping frequently detects lineage-unrelated receptors. Here, we report that surface receptors can be transferred from primary macrophages to CD4 T cells and identify the Fcγ receptor CD32 as driver and cargo of this trogocytotic transfer. Filamentous CD32+ nanoprotrusions deposit distinct plasma membrane patches onto target T cells. Transferred receptors confer cell migration and adhesion properties, and macrophage-derived membrane patches render resting CD4 T cells susceptible to infection by serving as hotspots for HIV-1 binding. Antibodies that recognize T cell epitopes enhance CD32-mediated trogocytosis. Such autoreactive anti-HIV-1 envelope antibodies can be found in the blood of HIV-1 patients and, consistently, the percentage of CD32+ CD4 T cells is increased in their blood. This CD32-mediated, antigen-independent cell communication mode transiently expands the receptor repertoire and functionality of immune cells. HIV-1 hijacks this mechanism by triggering the generation of trogocytosis-promoting autoantibodies to gain access to immune cells critical to its persistence.

Anti-human CD209, clone C209NeoBiotechnologiesCat#30835-MSM1-P1ABX

Keywords: immune cell communication, trogocytosis, CD32, autoantibodies, HIV reservoir, CRISPR-Cas9


Publication History:
Cell Rep Med. 2024 Apr 4;5(4):101483. doi: 10.1016/j.xcrm.2024.101483

Footnotes:
Supplemental information can be found online at https://doi.org/10.1016/j.xcrm.2024.101483.

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK